Embolic Protection Devices Market to Reach USD 1250 Million by 2032

According to analysts at Vantage Market Research, the Global Embolic Protection Devices Market size is worth USD 601 Million in 2023 and is projected to reach USD 1250 Million by 2032, growing at a CAGR (Compound Annual Growth Rate) of 8.5% from 2024 to 2032. The Embolic Protection Devices Market is driven by the rising prevalence of cardiovascular and neurovascular diseases, technological advancements, and the growing adoption of minimally invasive procedures. Opportunities include the increasing healthcare investments, an aging population, and ongoing innovation in device technology, which enhance patient safety and procedural outcomes.

Market Overview

The rising prevalence of cardiac conditions is escalating the demand for percutaneous coronary interventions, subsequently increasing the need for interventional cardiology and peripheral vascular devices. The CDC reports that coronary artery disease (CAD) is the most prevalent heart disease in the U.S., driving higher product demand. Additionally, embolic protection devices, known for their effectiveness in minimizing major adverse cardiovascular events and periprocedural myocardial infarction during SVG procedures, are anticipated to see greater adoption through 2032.

Advancements and innovations in embolic protection devices are expected to improve the market outlook in the coming decade. New technologies, including distal occlusion devices, distal filter devices, and proximal occlusion/flow-reversal devices, are designed to prevent embolic debris during endovascular procedures. For instance, Medtronic’s Mo.Ma Ultra proximal cerebral protection device uses a dual-balloon occlusion system to provide proximal protection before addressing a carotid lesion. Continued research and development focused on enhancing the effectiveness, safety, and ease of use of these devices are likely to boost their widespread adoption.

Contego Medical LLC Achieves CE Mark Approval for Innovative Neuroguard IEP 3-in-1 Carotid Stent System

Contego Medical LLC, a prominent innovator in cardiovascular devices, reached a notable achievement by securing the prestigious CE Mark approval for its advanced Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection. This development marks a significant advancement in interventional cardiology. The Neuroguard IEP System integrates cutting-edge embolic protection mechanisms with its carotid stent and post-dilation balloon, offering multiple approaches to addressing embolic risks simultaneously.

Key Takeaways from the Report

• In 2023, North America led the market with a 36.5% share, largely due to the rising prevalence of cardiovascular and neurovascular diseases in the region
• The Asia Pacific region is expected to experience rapid growth in the global market during the forecast period
• The Distal Filter Devices segment captured a significant market share in 2023, owing to their essential function in preventing embolic debris from reaching the brain during cardiovascular and neurovascular procedures
• The Cardiovascular Diseases segment was the market leader in 2023, holding 42.1% of the share, driven by the widespread occurrence of cardiovascular disorders worldwide

Top Companies

• Medtronic Plc
• Boston Scientific Corp.
• Abbott Laboratories
• Cordis (Cardinal Health Inc.)
• Allium Medical Solutions Ltd.
• Contego Medical
• Gore Medical
• Innovative Cardiovascular Solutions LLC
• Transverse Medical Inc.
• Silk Road Medical
• Edward Lifesciences

Latest News

Boston Scientific Announces PROTECTED TAVR Clinical Trial Results for SENTINEL Cerebral Protection System

• In September 2022, Boston Scientific Corporation disclosed the findings of the PROTECTED TAVR clinical trial, which evaluated the SENTINEL Cerebral Protection System. This device is designed to capture and remove embolic debris generated during transcatheter aortic valve replacement (TAVR) procedures, preventing it from reaching the brain and potentially causing a stroke.